Last reviewed · How we verify

NCT04597489: FLORIDA

Fractional FLOw Reserve In Cardiovascular DiseAses

Completed Last updated 22 October 2020
What this trial tests

trial testing Fractional flow reserve in Coronary Artery Disease in 64,045 participants. Completed in 2 March 2020.

Timeline
1 December 2019
Primary endpoint
20 January 2020
2 March 2020

Quick facts

Lead sponsorLinkCare GmbH
StatusCompleted
Study typeOBSERVATIONAL
Enrollment64,045
Start date1 December 2019
Primary completion20 January 2020
Estimated completion2 March 2020
Sites1 location across Germany

Drugs / interventions tested

Conditions studied

Sponsor

LinkCare GmbH — full company profile →

Who can join

Eligibility, any sex, with Coronary Artery Disease or Acute Coronary Syndrome. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

The FLORIDA (Fractional FLOw Reserve In cardiovascular DiseAses) study sought to investigate outcomes of FFR-guided versus angiography-guided treatment strategies in a large, real-world cohort.

Publications & conference data

1 peer-reviewed publication reference this trial (live from Europe PMC):

  1. Fractional flow reserve measurements and long-term mortality-results from the FLORIDA study.
    Boeckling F, Stähli BE, Rudolph T, Lutz M, et al · · 2024 · cited 1× · PMID 38404721 · DOI 10.3389/fcvm.2024.1337941

Verify or expand the search:

Other trials of Fractional flow reserve

Trials testing the same drug.

Other recruiting trials for Coronary Artery Disease

Currently open trials in the same condition.

Other LinkCare GmbH trials

Trials by the same sponsor.

Verify against primary sources

Data sources for this page

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT04597489.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing